Profil
Michelle Rashford is currently the Chief Medical Officer at Race Oncology Ltd.
Prior to this, she was the Vice President-Medical Science at Kyowa Kirin, Inc. from 2020 to 2022 and the Senior Vice President-Clinical Science at Hangzhou Adlai Nortye Biopharma Co. Ltd.
from 2018 to 2020.
Aktive Positionen von Michelle Rashford
| Unternehmen | Position | Beginn |
|---|---|---|
| RACE ONCOLOGY LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2023 |
Ehemalige bekannte Positionen von Michelle Rashford
| Unternehmen | Position | Ende |
|---|---|---|
| Kyowa Kirin, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2022 |
Hangzhou Adlai Nortye Biopharma Co. Ltd.
 Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2020 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RACE ONCOLOGY LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Hangzhou Adlai Nortye Biopharma Co. Ltd.
Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then. | Health Technology |
| Kyowa Kirin, Inc. |
